Matches in Wikidata for { <http://www.wikidata.org/entity/Q65316726> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q65316726 description "assaig clínic" @default.
- Q65316726 description "clinical trial" @default.
- Q65316726 description "clinical trial" @default.
- Q65316726 description "clinical trial" @default.
- Q65316726 description "clinical trial" @default.
- Q65316726 description "ensaio clínico" @default.
- Q65316726 description "ensayo clínico" @default.
- Q65316726 description "ensayu clínicu" @default.
- Q65316726 description "essai clinique" @default.
- Q65316726 description "klinisch onderzoek" @default.
- Q65316726 description "клінічне випробування" @default.
- Q65316726 name "Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)" @default.
- Q65316726 name "Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin" @default.
- Q65316726 type Item @default.
- Q65316726 label "Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)" @default.
- Q65316726 label "Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin" @default.
- Q65316726 prefLabel "Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)" @default.
- Q65316726 prefLabel "Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin" @default.
- Q65316726 P1050 Q65316726-F4D45355-0697-4F51-930A-C6AD34BF2A99 @default.
- Q65316726 P1132 Q65316726-B70CE380-2E93-422B-A616-22987294E271 @default.
- Q65316726 P1476 Q65316726-B8FF6B43-AA20-4806-A2AC-273808BE740B @default.
- Q65316726 P2899 Q65316726-2A0233AF-0A99-42B8-9AC1-B4CA3BA3DEE6 @default.
- Q65316726 P3098 Q65316726-D5E053CE-C30C-49E0-AEAA-0028960598F4 @default.
- Q65316726 P31 Q65316726-9D6C474A-BC72-4BDB-81B0-C62193ED2C88 @default.
- Q65316726 P4844 Q65316726-5CB260CB-1069-41DE-A9F0-FD421B40C725 @default.
- Q65316726 P580 Q65316726-164E04DB-D0EB-4BE6-BB2C-51C2F421A68C @default.
- Q65316726 P582 Q65316726-2DB35FCF-B886-461D-9F67-DFDA04EA0E7E @default.
- Q65316726 P6099 Q65316726-28C7069E-53A6-4376-933B-5AAE2D032231 @default.
- Q65316726 P8363 Q65316726-1BA9C800-0CFD-426B-A009-2AC55C25855E @default.
- Q65316726 P1050 Q12206 @default.
- Q65316726 P1132 "+143" @default.
- Q65316726 P1476 "A Phase III, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial to Assess the Safety and Efficacy of Addition of Ipragliflozin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin Monotherapy in Addition to Diet and Exercise Therapy" @default.
- Q65316726 P2899 "+20" @default.
- Q65316726 P3098 "NCT02577003" @default.
- Q65316726 P31 Q30612 @default.
- Q65316726 P4844 Q17193526 @default.
- Q65316726 P580 "2015-11-09T00:00:00Z" @default.
- Q65316726 P582 "2016-11-25T00:00:00Z" @default.
- Q65316726 P6099 Q42824827 @default.
- Q65316726 P8363 Q78089383 @default.